Home Spirometry for Post-COVID Recovery: A Clinical Validation Study of an Ultrasonic Device.

Patients recovering from COVID-19 often experience persistent respiratory symptoms, necessitating pulmonary function monitoring. While clinical spirometry is the gold standard, home spirometry offers a remote alternative. This study evaluated the validity of an ultrasonic home-based spirometer for monitoring lung function in post-COVID-19 pneumonia patients over 12 weeks. : This prospective study included 30 post-COVID pneumonia patients who underwent clinical spirometry at weeks 4, 8 and 12. Participants performed weekly home spirometry using the SpiroHome Personal device. Agreement between home and clinical spirometry was assessed using a Bland-Altman analysis, intraclass correlation coefficients (ICCs), and Pearson correlation coefficients. Pulmonary function changes over time were analyzed using repeated measures ANOVA. : Home spirometry showed strong agreement with clinical spirometry for forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1), with ICC values exceeding 0.92. The Bland-Altman analysis demonstrated minimal bias, though limits of agreement exceeded the clinically accepted threshold of ±150 mL. FEV1/FVC ratios showed greater variability. Pulmonary function improved significantly over 12 weeks for both methods ( < 0.002). Patient adherence to home spirometry remained high, with a median of 18.50 sessions [IQR: 15.00-26.00] and an overall compliance rate of 98.33% ± 9.13%. : Home spirometry provides reliable pulmonary function measurements, particularly for FVC and FEV1, supporting its role as a remote monitoring tool. Despite minor variability in FEV1/FVC, home spirometry enables frequent assessment of lung function recovery, potentially reducing hospital visits and improving patient management.